These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18237851)

  • 1. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
    Sève P; Dumontet C
    Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P; Dumontet C
    Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
    Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.
    Sève P; Mackey J; Isaac S; Trédan O; Souquet PJ; Pérol M; Lai R; Voloch A; Dumontet C
    Mol Cancer Ther; 2005 Dec; 4(12):2001-7. PubMed ID: 16373715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
    Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
    Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
    English DP; Roque DM; Santin AD
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
    J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
    Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
    Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
    Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.